Whether Gilteritinib is a medical insurance drug and explanation of reimbursement policy

Gilteritinib (Gilteritinib) is already on the market in China, but it has not yet been included in the national medical insurance system. This means that when patients purchase the drug in domestic hospitals, they need to bear all costs themselves, and medical insurance reimbursement cannot cover it. This increases the financial burden on patients to a certain extent and may also affect the accessibility of drugs.

Since domestic medical insurance does not yet cover it, the supply of gilitinib in hospitals may be relatively limited. If patients need medication, they usually need to consult the local hospital pharmacy in advance or make an appointment to purchase medication through specific channels. Doctors will also provide individualized treatment plans based on the patient's condition and financial situation.

In overseas markets, gilitinib provides more choices. The original drugs mainly include the European version and the Hong Kong version. The price of the Hong Kong version is as high as 100,000 yuan, which is expensive and not suitable for long-term use by most patients. In comparison, overseas generic drugs are more affordable, especially the Laos version, which costs more than one thousand to two thousand yuan. The ingredients of the drugs are basically the same as those of the original drugs, providing a viable option for patients with limited financial conditions.

Generally speaking, giritinib has not been included in medical insurance in China, so patients need to bear higher costs themselves or obtain it through overseas channels. When choosing drug purchase channels, patients should fully understand the authenticity, quality assurance and price differences of the drugs to ensure drug safety and therapeutic effect, and at the same time cooperate with doctors to formulate a reasonable medication plan.

Reference materials:https://www.drugs.com/